Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815471 | 0.94 | SLC6A4 (0.38) | SLC6A4MAOARAB9AGAANPC1 | |
| SCHEMBL17811481 | 0.89 | PLK1 (0.39) | SLC6A4RAB9AGAANPC1ALDH1A1 | |
| SCHEMBL18902801 | 0.89 | SLC6A4 (0.31) | SLC6A4MAOA | |
| SCHEMBL17811486 | 0.86 | MAOA (0.40) | SLC6A4MAOARAB9ANPC1TAS1R3 | |
| SCHEMBL17811484 | 0.82 | SLC6A4 (0.36) | SLC6A4MAOARAB9AGAANPC1 | |
| SCHEMBL17815472 | 0.79 | MAOA (0.43) | MAOARAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL17815538 | 0.74 | SLC6A4 (0.40) | SLC6A4MAOARAB9AGAANPC1 | |
| SCHEMBL13940796 | 0.73 | SLC6A4 (0.48) | SLC6A4MAOAALDH1A1 | |
| SCHEMBL17815438 | 0.71 | NR1H2 (0.37) | GAACYP1A2 | |
| SCHEMBL20306694 | 0.69 | ALDH1A1 (0.43) | RAB9AGAANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | TRINSEO EUROPE GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | ELOVL5, ELOVL3, ELOVL1 | SLC6A4 4512/4885MAOA 1229/4885RAB9A 4875/4885 |
| US-20160159956-A1 | Polymerisation Initiators | ELOVL5, ELOVL3, ELOVL1 | SLC6A4 4512/4885MAOA 1229/4885RAB9A 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.